RAPID MICRO BIOSYS.A -,01

Rapid Micro reported Q2 revenue of $8.1 million (+11% y/y), beating the $7.85 million forecast. Gross margin improved to 15% (vs. 4% a year ago) and consumables revenue rose by more than 20% to a quarterly record; nine validations were completed and the annual target was raised to at least 27 validations. The company reaffirmed its full-year revenue guidance of $37–41 million and expects Q3 revenue of at least $9.5 million as well as lower cash burn in H2, but remains unprofitable with a net loss of $12.9 million. The stock fell slightly in pre-market trading (-1.46%), suggesting investor caution given the ongoing losses. » More on de.investing.com

Rapid Micro Biosystems reported Q1 2026 revenue of $8.0M (+11% y/y), driven by a 36% increase in product revenue, beating the revenue expectation of $7.63M. Earnings per share of -$0.31 were worse than the expected -$0.25, a negative surprise of 24%. Operating expenses rose partly due to one‑time charges, and the company remains unprofitable. Management issued revenue expectations of $7.8M for Q2 and $10.55M for Q3; the stock rose moderately in after‑hours trading. » More on de.investing.com

Rapid Micro Biosystems announced that COO John Wilson will leave the company on April 10, 2026, and that CEO Robert Spignesi will take on operational leadership from that date. Wilson entered into a consulting and termination agreement, will remain available as a consultant through June 30, 2026 (USD 200/hour, max. 20 hours/month), receives an extended exercise period for options until March 31, 2027, and is subject to share sale restrictions. The company reported Q4 2025 revenue of USD 11.3 million (above expectations) and a diluted net loss per share of USD 0.28; Stifel reiterated a "Buy" rating with a USD 8.00 price target and noted margin pressure from an inventory write-down. Management expects gross margins of 20% by 2026. » More on de.investing.com